Two Sigma Advisers
REGN icon

Two Sigma Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Two Sigma Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,000
Closed -$313K – 2498
2013
Q3 		$313K Buy
+1,000
New +$263K ﹤0.01% 1680

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Advisers's REGN Position: Q1 2026 in Review

Two Sigma Advisers sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 604,540 shares — an estimated $467M sold.

Two Sigma Advisers first reported a position in REGN in Q2 2013 and held it in 41 quarters. The position peaked at $521M in Q3 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Two Sigma Advisers reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 604,540 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $467M.
  • Two Sigma Advisers first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 41 quarters.
  • Two Sigma Advisers's Regeneron Pharmaceuticals position peaked at $521M in Q3 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.